Skip to Content

Iohexol Pregnancy and Breastfeeding Warnings

Iohexol is also known as: Myelo-Kit, Omnipaque 140, Omnipaque 180, Omnipaque 180 Redi-Unit, Omnipaque 210, Omnipaque 240, Omnipaque 240 Redi-Unit, Omnipaque 300, Omnipaque 350, Omnipaque Flexipak, Oraltag

Iohexol Pregnancy Warnings

This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus. AU TGA pregnancy category: Not assigned. US FDA pregnancy category: B

Reproduction studies have been performed in rats and rabbits with up to 100 times the recommended human dose. No evidence of direct or indirect impaired fertility, harm to the embryo, fetus, or to the course of gestation and peri and postnatal development has been demonstrated. There are no controlled data in human pregnancy. US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

See references

Iohexol Breastfeeding Warnings

Caution is recommended. Excreted into human milk: Yes Comments: -Bottle feedings may be substituted for breast feedings for 24 hours following administration of this drug; however, some experts feel that breast feeding may be continued normally when iodinated contrast media are given to the mother. -The effects in the nursing infant are unknown.

Contrast media are poorly excreted in human breast milk and minimal amounts are absorbed by the intestine. Approximately 0.5% of the weight adjusted maternal dose is excreted in breast milk during 24 hours after injection of this drug. The amount ingested by the baby in the first 24 hours after injection corresponds to only 0.2% of the pediatric dose.

See references

References for pregnancy information

  1. "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.